Hans-Peter Kiem, MD, PhD

Fred Hutch Endowed Chair for Cell and Gene Therapy
Clinical Research Division
Director, Cell and Gene Therapy Program
Clinical Research Division
Associate Head of Transplantation Biology
Clinical Research Division
Professor of Medicine / Oncology and Pathology
University of Washington School of Medicine
Associate Head, Heme Malignancy Program
UW / Fred Hutch Cancer Consortium

Additional Appointments

Jose Carreras / E. Donnall Thomas Endowed Chair for Cancer Research 2009-2014
Fred Hutchinson Cancer Research Center

Attending Physician, Medical Oncology
Seattle Cancer Care AllianceFred Hutchinson Cancer Research Center and University of Washington

Medicine Qualifications

M.D., University of Ulm, Medicine, 1987
Ph.D., University of Ulm, Medicine, 1988

Expertise and Research Interests

Dr. Kiem’s research has focused on stem cell and transplantation biology, cell and gene therapy and the development and use of novel gene editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer. Dr. Kiem has extensive experience training students and postdoctoral fellows and has mentored more than 50 trainees in his lab over the past 20 years. Many of his trainees now hold tenured faculty positions in the US and in Germany. Dr. Kiem is the Sponsor of 4 clinical gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and he is the PI or Co-PI of many R01 or P01 grants including a Martin Delaney Consortium grant to study HIV cure strategies (defeatHIV). Dr. Kiem has also served on the NIH Recombinant DNA Advisory Committee (RAC) for 5 years and the last year as Chair. He is currently the Chair of the Stem Cell Committees for both the American Society for Gene and Cell Therapy (ASGCT) and the American Society of Hematology.

The current research in our laboratory focuses on studies to:

  • Understand basic hematopoietic stem cell (HSC) and transplantation biology and clonal composition of hematopoiesis after transplantation, especially the clonality of gene-modified HSCs
  • Develop and evaluate novel virus-based gene therapy technology and nuclease technology including megaTals, zinc finger nucleases and CRISPR/Cas technology to edit hematopoietic cells with the goal to improve the treatment for genetic and infectious diseases and cancer.
  • Develop novel ways to derive HSCs from induced pluripotent stem cells (iPSCs) and to expand HSCs to facilitate gene therapy and stem cell transplantation
  • Develop clinical gene therapy protocols for genetic and acquired diseases, including cancer. Current target diseases include Fanconi anemia, severe combined immunodeficiency, hemoglobinopathies, glioblastoma, and HIV
  • Develop less toxic hematopoietic cell transplantation protocols especially for patients with nonmalignant diseases

Clinical Trials


  • Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients with HIV-Associated Lymphoma (ClinicalTrials.gov Identifier NCT02378922)
  • HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients with Lymphoma With HIV Infection (ClinicalTrials.gov Identifier NCT02343666

Fanconi Anemia

  • Gene Therapy for Fanconi Anemia (ClinicalTrials.gov Identifier NCT01331018)


  • Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas (ClinicalTrials.gov Identifier NCT00669669)

Related News

Hans-Peter Kiem, MD, PhD

Contact Information

(206) 667-4409
(206) 667-6124
Additional contact

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
P.O. Box 19024
Seattle, Washington 98109-1024
United States